Clinical correlation of extensive-stage small-cell lung cancer genomics

Annals of Oncology

Volumn 27, Issue 4, 2016, Pages 642-647

  Dowlati, A ^a   Lipka, M B ^a   McColl, K ^a   Dabir, S ^a   Behtaj, M ^a   Kresak, A ^a   Miron, A ^a   Yang, M ^a   Sharma, N ^a   Fu, P ^b   Wildey, G ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene mutations; Genomic analysis; RB1; Small cell lung cancer; Survival; TP53

Indexed keywords

EPHRIN RECEPTOR B1; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR RECEPTOR 1; INTERLEUKIN 7 RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN PATCHED 1; PROTEIN RET; RETINOBLASTOMA BINDING PROTEIN 2; VASCULOTROPIN RECEPTOR 1; FGFR1 PROTEIN, HUMAN; RETINOBLASTOMA PROTEIN; TP53 PROTEIN, HUMAN;

ARID1A GENE; ARID1B GENE; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREBBP GENE; DNA SEQUENCE; EPHB1 GENE; FEMALE; FGF10 GENE; FGFR1 GENE; FLT1 GENE; GENE; GENE MUTATION; GENETIC REGULATION; GENOMICS; GPR124 GENE; HUMAN; HUMAN CELL; IL7R GENE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIT GENE; LOGISTIC REGRESSION ANALYSIS; MALE; MLL2 GENE; MLL3 GENE; MYST3 GENE; NOTCH1 GENE; NOTCH2 GENE; NTRK1 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PTCH1 GENE; PTEN GENE; RB1 GENE; RET GENE; RICTOR GENE; RPTOR GENE; SMALL CELL LUNG CANCER; TARGETED EXOME SEQUENCING; TP53 GENE; TREATMENT RESPONSE; TSC2 GENE; WESTERN BLOTTING; WHOLE EXOME SEQUENCING; WILD TYPE; ZNF703 GENE; ADULT; AGED; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENOMICS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RETINOBLASTOMA PROTEIN; SMALL CELL LUNG CARCINOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84964670616     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw005     Document Type: Article

References (20)

1. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539-4544.
2. Kalemkerian GP, Akerley W, Bogner P et al. Small cell lung cancer. J Natl Compr Canc Netw 2013; 11: 78-98.
3. Pietanza MC, Byers LA, Minna JD, Rudin CM. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res 2015; 21: 2244-2255.
4. Nickolich M, Babakoohi S, Fu P, Dowlati A. Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution. Clin Lung Cancer 2014; 15: 207-212.
5. Ott PA, Fernandez MEE, Hiret S et al. Pembrolizumab (MK-3475) in patients with extensive-stage small cell lung cancer: preliminary safety and efficacy results from KEYNOTE-028. J Clin Oncol 2015: 33 (suppl); abstr 7502.
6. Rudin CM, Durinck S, Stawiski EW et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012; 44: 1111-1116.
7. Peifer M, Fernandez-Cuesta L, Sos ML et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012; 44: 1104-1110.
8. George J, Lim JS, Jang SJ et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015; 524: 47-53.
9. Barretina J, Caponigro G, Stransky N et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
10. Liang W, Zhang Y, Kang S et al. Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis. J Thorac Dis 2014; 6: 1239-1250.
11. Fang S, Wang Z, Guo J et al. Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer. Onco Targets Ther 2014; 7: 1185-1193.
12. Umemura S, Mimaki S, Makinoshima H et al. Therapeutic priority of the PI3K/AKT/ mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol 2014; 9: 1324-1331.
13. Johnson BE, Ihde DC, Makuch RW et al. myc Family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest 1987; 79: 1629-1634.
14. Melichar B, Adenis A, Lockhart AC et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol 2015; 16: 395-405.
15. Nakai M, Hashikura Y, Ohkouchi M et al. Characterization of novel germline c-kit gene mutation, KIT-Tyr553C, observed in a family with multiple gastrointestinal stromal tumors. Lab Invest 2012; 92: 451-457.
16. Krampitz GW, Norton JA. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Cancer 2014; 120: 1920-1931.
17. Dabir S, Babakoohi S, Kluge A et al. RET mutation and expression in small-cell lung cancer. J Thorac Oncol 2014; 9: 1316-1323.
18. Iwasaki JK, Srivastava D, Moy RL et al. The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics. J Am Acad Dermatol 2012; 66: e167-e178.
19. Witkiewicz AK, Ertel A, McFalls J et al. RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2012; 18: 5110-5122.
20. Molina-Vila MA, Bertran-Alamillo J, Gasco A et al. Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Clin Cancer Res 2014; 20: 4647-4659.